News brief­ing: Cosen­tyx shows ear­ly pos­i­tive signs in pso­ri­at­ic arthri­tis; Pfiz­er's PhI­Ib for car­dio drug trig­gers $75M mile­stone

No­var­tis’ block­buster Cosen­tyx is seek­ing ap­proval in an­oth­er in­di­ca­tion, and the com­pa­ny re­port­ed pos­i­tive ear­ly Phase II­Ib re­sults Thurs­day.

Look­ing to re­duce joint lin­ing in­flam­ma­tion in pso­ri­at­ic arthri­tis, Cosen­tyx saw ben­e­fits against place­bo af­ter 12 weeks. Though No­var­tis didn’t pro­vide any num­bers in this ear­ly look, the com­pa­ny said the drug showed “sig­nif­i­cant ben­e­fit” on its way to meet­ing the pri­ma­ry end­point.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER